Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Oct 20;30(1):47.
doi: 10.1038/s41533-020-00207-7.

Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients

Björn Ställberg  1 , Christer Janson  2 , Karin Lisspers  3 , Gunnar Johansson  3 , Florian S Gutzwiller  4 , Karen Mezzi  4 , Bine Kjoeller Bjerregaard  5 , Anne Mette Tranberg Kejs  5 , Leif Jorgensen  5 , Kjell Larsson  6
Affiliations
Observational Study

Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients

Björn Ställberg et al. NPJ Prim Care Respir Med. .

Abstract

This study reports the association of ICS use and the risk of type 2 diabetes mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary care settings. A total of 7078 patients with COPD were included in this analysis and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of ICS especially at a high dose in patients with COPD was related to an increased risk of T2DM.

PubMed Disclaimer

Conflict of interest statement

B.S. reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline, Meda, Teva, and Chiesi, outside the submitted work. C.J. reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Teva, outside the submitted work. K. Lisspers reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline, and Chiesi, outside the submitted work. G.J. has participated in the steering committee organised by Novartis for this study and served on advisory boards arranged by AstraZeneca, Novo Nordisk, and Takeda. F.S.G. and K.M. are employees of Novartis Pharma AG. B.K.B., L.J., and A.M.T.K. are employees of IQVIA and have received remuneration in relation to statistical analyses. K. Larsson has, during the past 5 years, on one or more occasion served in an advisory board, served as a speaker, and/or participated in education activities arranged by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Chiesi, Sanofi, Novartis, Orion, and Teva.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008;32:962–969. doi: 10.1183/09031936.00012408. - DOI - PubMed
    1. Price DB, et al. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. NPJ Prim. Care Respir. Med. 2019;29:38. doi: 10.1038/s41533-019-0150-x. - DOI - PMC - PubMed
    1. Rana JS, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004;27:2478–2484. doi: 10.2337/diacare.27.10.2478. - DOI - PubMed
    1. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010;123:1001–1006. doi: 10.1016/j.amjmed.2010.06.019. - DOI - PubMed
    1. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br. J. Clin. Pharmacol. 2002;54:59–64. doi: 10.1046/j.1365-2125.2002.01610.x. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances